The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.

The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.

The announcement comes on the heels of promising preliminary Phase II data, in which OCU410 reduced lesion growth in patients' eyes.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...